Mohammad Sahtout
4 Papers
Mohammad Sahtout is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
John G. Strickler,Antonio Cubillo,Jin-Tung Liang,Marc R. Matrana,Mark Kozloff,Thomas Lowe,Martha Blaney,Mohammad Sahtout,Louie Naumovski,O. Wainberg +9 more
TL;DR: Treatment with dilpacimab + FOLFIRI was not well tolerated and did not provide clinical benefit to patients with mCRC compared with bevacizumab + F OLFIRI.
7
770 Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors
Anthony W. Tolcher,Desamparados Roda-Perez,Kai He,Victor Moreno,Carlos Gomez-Roca,Jean-Pascal Machiels,Albiruni R. Razak,Mohammad Sahtout,Xiaowen Guan,Stacy Jaryno-Daly,Rachel S. Leibman,Martha Blaney,James O’Brien,Patricia LoRusso,John D. Powderly,Talia Golan,Kathy Miller,Jordi Bruix +17 more
- 01 Nov 2022
TL;DR: AbbVie et al. as discussed by the authors reported preliminary safety, efficacy, and pharmacokinetic (PK) results from a first-in-human, phase 1 study assessing ABBV-151 ± budigalimab in adult patients (≥18 years) with locally advanced/metastatic solid tumors.
4
Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.
Desamparados Roda,Jean-Pascal Machiels,Chang-Fang Chiu,Shunsuke Kondo,Victor Ricardo Adorno Febles,Victor Moreno,Chia-chi Lin,Sun Young Rha,Sarid David,Albiruni Ryan Abdul Razak,S. Kao,Maulik Patel,Mohammad Sahtout,Jonathan Deutsch,Duyen Ngo,Cristiano Ferlini,Kai He +16 more
TL;DR: Livmoniplimab (livmo) with or without budigalimab (budi) shows promising efficacy and manageable safety in patients with advanced urothelial carcinoma, with a 24% best response rate and 18% confirmed ORR, comparable to CPI-naive patients with pembrolizumab or nivolumab monotherapy.
Abstract CT109: Livmoniplimab and budigalimab combination therapy in treating patients with metastatic ovarian granulosa cell tumors: Results from dose escalation in a first-in-human study
Ildefonso Rodriguez Rivera,David Sommerhalder,Mohammad Sahtout,Cristiano Ferlini,Duyen Ngo,Sujata Jha,John Engelhardt,Anthony W. Tolcher +7 more
TL;DR: OGC is a proof-of-mechanism indication for livmo and that targeting TGF-β may represent an effective strategy for treating pts with OGC, a rare TGF-β signaling-dependent tumor.